Fiche centre
Brain Matters Research
Delray Beach — United States
Essais liés10clinical trials
VilleDelray Beachlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT02008357
Essais cliniques associés
10| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Low Dose Benfotiamine | Alzheimer | Phase 2 | NCT06223360 | A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) | ACTIVE_NOT_RECRUITING |
| Spectris™ AD - Active | Alzheimer | Non applicable | NCT05637801 | A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) | COMPLETED |
| ONO-2020 | Alzheimer | Phase 2 | NCT06881836 | A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| ITI-1284 | Alzheimer | Phase 2 | NCT06651567 | A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia | RECRUITING |
| ITI-1284 | Alzheimer | Phase 2 | NCT06540833 | A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease | RECRUITING |
| Solanezumab | Alzheimer | Phase 3 | NCT02008357 | A4 — Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss | COMPLETED |
| Donanemab | Alzheimer | Phase 2 | NCT07589595 | A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) | RECRUITING |
| LHP588 | Alzheimer | Phase 2 | NCT06847321 | Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease | RECRUITING |
| CT1812 | Alzheimer | Phase 2 | NCT05531656 | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING |